Maxim Group analyst Jason Kolbert reiterated a Buy on Gilead Sciences (NASDAQ: GILD) and raised his price target from $98 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE